Compare Crispr Therapeutics AG (CRSP) vs 8x8 Inc (EGHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs 8x8 Inc — how do they compare? Crispr Therapeutics AG trades at $53.51 (market cap $4.88B), while 8x8 Inc trades at $2.13 (market cap $311.98M). The key difference: Crispr Therapeutics AG is far larger — about 15.6× 8x8 Inc's market cap, and 8x8 Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and 8x8 Inc for 16 Days on average.
| CRSP | EGHT | |
|---|---|---|
Market Cap | $4.88B | $311.98M |
Volume | 2,861,747 | 1,639,086 |
Sector | Health | Technology |
52-Week High | $74.92 | $2.76 |
52-Week Low | $44.34 | $1.59 |
Typical Hold Time | 77 Days | 16 Days |
Enterprise Value | $3.30B | $578.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
EGHT trades at $2.15, up 0.47% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $27.21M in 2025 but shows improving trends with revenue growth to $745M and a projected net profit of $5M in 2026. Recent news highlights cost-saving client wins and AI product growth, while analyst consensus is a Buy with a $19.77 price target, suggesting significant upside potential from current levels.
The outlook is cautiously optimistic, with earnings beats and projected profitability offering opportunity, but high debt and thin margins pose risks. Investor sentiment is mixed amid valuation concerns, yet institutional interest and strategic partnerships support a positive long-term view if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
